MOLOGNI LUCA
- U08, Floor: 4, Room: LABORATORIO 4.10
- U08, Floor: 4, Room: 4043
Publications
Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail
Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. LEUKEMIA, 38(8), 1843-1847 [10.1038/S41375-024-02282-Y]. Detail
Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Detail
Villa, M., Geeta, G., Malighetti, F., Mauri, M., Arosio, G., Cordani, N., et al. (2024). Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. BRITISH JOURNAL OF CANCER [10.1038/s41416-024-02881-7]. Detail
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD, 143(14), 1399-1413 [10.1182/blood.2023021349]. Detail